Chapter 84 Medical Insurance Emergency Meeting
On the other side,
Su Province, the atmosphere in the General Manager Office of Hengrui Pharmaceutical was far from so relaxed.
"Wenping, do you think the 90% probability of the cure they advertise will be successful?"
Su Wenping sat on a chair and did not answer Su Lin's question immediately.
After being silent for about two or three seconds, he slowly said:
"Boss, based on my understanding of Qingshan Pharmaceutical, I should be close to you."
"Hey, that's right... ..."
Su Lin sighed slightly and sighed. :
“At the very beginning, we were still full of hope and wanted to compete with Gilead for the ‘Starlight Project’, but no one thought that we would not be able to do it, and Gilead would not succeed either. On the contrary, Tsingshan Pharmaceuticals was so successful. Break out! ”
"Their progress is too fast."
Su Lin also sighed helplessly, his mood obviously depressed.
In fact,
he really paid enough attention to Qingshan Pharmaceutical, especially when "QS-001" just entered the second clinical phase last time, he immediately focused on it and started collecting information .
But even so, the progress of Qingshan Pharmaceutical far exceeded his expectations.
At this moment, Su Lin continued:
“That’s it, Wenping, since they have made breakthrough progress, let’s stop here with our hepatitis B drug ‘HR-006’.”
"In a moment, you will inform the R&D department that the 'HR-006' project has been officially stopped, and all R&D personnel will be transferred to other projects."
Hearing this, Su Wenping was stunned at first, and then his heart flashed. What a pity.
In this year, he has been staring at the "HR-006" project almost every day. It would be a lie to say that he has no feelings at all!
And...
The "HR-006" project is actually not progressing at all. On the contrary, it is progressing very smoothly, but it is not as fast as Tsingshan Pharmaceutical's "QS-001".
If you continue to persist, "HR-006" may not be able to cure hepatitis B in its own way.
Thinking of this, he couldn't help but said:
"Boss, the 'HR-006' project is actually making good progress. The rate of effectively preventing hepatitis B synthesis has reached 40% in the past few months. , the latest test last month increased to 50%.”
"If we persist a little longer, maybe we can cure hepatitis B in another way. Moreover, our method has almost no toxic side effects and is much better than Qingshan Pharmaceutical..."
His words Before he could finish speaking, Su Lin waved his hand and interrupted:
“That’s not necessary, Wenping, a domestic hepatitis B patient. About 100 million. "
"Once Qingshan Pharmaceutical's drugs are launched, they will quickly occupy the market. Even if we make a breakthrough, we will only be eating scraps and not making much money. "
"If you have this time, you might as well focus on the research and development of other drugs that are more likely to make money."
Su Wenping was silent. Su Lin's consideration was based on maximizing the company's commercial profits, which was not wrong.
“In that case, do you think we should organize all the researchers in the project team to learn the unique ideas of Qingshan Pharmaceutical’s ‘Ecofovir’?”
“Their ideas for solving hepatitis B virus are very It’s novel, and it might help us develop other drugs.”
Su Lin was silent for a moment, and finally shook his head:
“There’s no rush for now, many of our drug research and development teams are here now. Critical time.”
"As you know, we are facing many competitors for several targeted drugs under development. Once we let the other party lead the progress, we will lose a lot of profits."
"So, wait until we have results. Let's talk after this." Su Lin pursed his lips and said nothing. For the first time, he felt that he and Mr. Su had some differences on the matter of research and development.
Suddenly, he thought of Qingshan Pharmaceutical and Zhang Yang.
What would Zhang Yang do if he encountered such a thing?
If "HR-006" is announced successfully before "QS-001", will Zhang Yang simply give up "QS-001"?
He doesn’t know.
……
Su Lin’s decision is not right or wrong.
Not only him, when the second phase clinical data of Tsingshan Pharmaceutical's "Ecofovir" was released and successfully approved for the third phase of clinical trials, most domestic pharmaceutical companies stopped the research and development of their own hepatitis B projects.
Only a handful of pharmaceutical companies have begun to try to learn the toxicity idea of "Ecofovir", hoping to apply this idea to other CCDNA covalently closed viruses that are the same as hepatitis B.
For example: HIV, Ebola and coronavirus.
Zhang Yang did not know the choices of various pharmaceutical companies. With 600 Phase III clinical trial participants actively signing up, on November 10, the Phase III clinical trial of "Ekofovir" officially began.
This time, since nearly a hundred people participated in each group, just after the drugs were distributed,
many patients started "drug trial live streaming" on multiple platforms such as Hepatitis B Bar, Douyin, and Station B. , start recording the change process of daily medication.
Originally, participants were required to sign a confidentiality agreement when participating in clinical trials, and subjects were not allowed to send data to the Internet.
But "Ekofuvir" itself is a complete product, there is no leakage of commercial secrets, and it can even be advertised, so publicity is simply ignored.
Gradually, a large amount of real data from subjects appeared on the Internet.
It was fine in the first two or three weeks, and the subjects did not turn negative. It was not until the fifth and sixth weeks that a large number of subjects turned negative and were cured in large areas.
Everyone is beginning to realize that Tsingshan Pharmaceutical’s claim that it is possible to achieve a 90% cure rate in the third phase of clinical trials is not a joke.
It might be true!
On January 12, just two days after the first batch of the third clinical phase of "Ecofovir" ended,
The organizer of "Starlight Project": "State Food and Drug Administration" , the "Innovative Drug Research and Development Center" urgently jointly held a seminar with 20 people in conjunction with the "Health Commission", "Medical Insurance Bureau" and other departments.
The meeting was chaired by Zhou Hai, deputy director of the project department of the "Innovative Drug Research and Development Center".
“Good afternoon to all distinguished leaders, experts in the medical field who have come from afar, and colleagues from various departments. Thank you all for taking the time out of your busy schedule to come to attend this seminar.”
"Everyone must have known the topic of the discussion in advance. It is about a drug recently developed by Tsingshan Pharmaceuticals that can cure hepatitis B - 'Acofenprofovir'."
With the simple As the opening remarks began, the conference room at the Shenzhen Innovative Drug Support Center gradually became quiet.
"The seminar will officially begin. First, let me give you a brief introduction to the current situation of 'Ikefenprovir'."
"Please look at the screen."
Zhou Hai gently pressed the projector pen in his hand, and a detailed data table appeared on the screen in front of the conference room.
"This is the clinical data of the second phase of the clinical trial of 'Acofovir'. It can be seen that their cure rate has increased from 25% to 40%, and finally the last group reached 60%!"
" And yesterday, we got all the data from the first batch of their latest clinical phase 3.”
(End of this chapter)